Aug 15, 2005
A recent New England Journal of Medicine article substantiated CepTor Corporation’s platform technology in the areas of Duchenne muscular dystrophy (DMD) and multiple sclerosis, verifying the role of calpain as a known causative in both conditions and touting calpain inhibition as a viable therapy. CepTor’s lead product, Myodur, targets DMD.
Albany Molecular Research Inc. (AMRI) announced a two-year research collaboration with the National Institute of Neurological Disorders and Stroke to develop treatments for spinal muscular atrophy, a degenerative neuromuscular disease. AMRI will provide fee-for-service medicinal chemistry lead optimization on target compounds, including design and synthesis of analogs and analysis of associated structure activity relationships.
San Diego-based Illumina began commercial shipment of its Sentrix Human-1 Genotyping BeadChip, which can interrogate more than 100,000 SNP loci per sample. This SNP content strategy is powered by Illumina’s Infinium assay, a genotyping method that offers virtually unconstrained locus selection and scalable assay multiplexing.